N6-methyladenosine: A pivotal regulator in glioma oncogenesis and progression

Gliomas are the most prevalent primary neoplasms of the central nervous system and arise from glial cells present in the brain or spinal cord. N6-methyladenosine (m6A) is one of the most frequently occurring modifications in RNA, and its potential implications in glioma have received widespread attention in recent years. In glioma, m6A-related enzymes are capable of modifying target RNAs, influencing their translation, degradation, and splicing, which can promote or inhibit biological processes such as ferroptosis and glycolysis, ultimately impacting the progression of glioma. Furthermore, upstream modulators are capable of regulating the expression of m6A-associated enzymes, ultimately affecting glioma development by modulating m6A modification on target RNAs. In addition, the m6A modification influences glioma resistance to temozolomide, resulting in an impact on glioma patient survival. This review comprehensively delineates the molecular mechanisms by which m6A and its upstream signaling molecules regulate glioma development, emphasizing their potential value in exploring new therapeutic approaches and improving patient prognosis.